External Advisory Board PDF Print E-mail

 

 

Within the framework of SCR&Tox an independent Advisory Board was set up with representatives of the big pharmaceutical and cosmetic industry, members of regulatory bodies interested in toxicology, as well as an ethical advisor.
The Advisory Board is invited to attend the annual consortium meetings in order to give their visions and advise in terms of work program, integration and project strategy and to provide an objective assessment of the scientific and innovation/exploitation-related issues.
As SCR&Tox will be implemented in full respect of the legal and ethical European/national/institutional requirements, for this, it has appointed an external independent Ethics Advisor to oversee the ethical concerns involved in SCR&Tox research
Members of the Advisory Board
Klaus- Dieter Bremm from Bayer
Philippe Detilleux from Sanofi-Aventis
Julie Holder, GlaxoSmithKline
Gladys Ouédraogo, L’Oréal – COLIPA
Laura Suter-Dick, Roche
ETHICS Advisor
Kristina Hug, Lund University

Within the framework of SCR&Tox an independent Advisory Board was set up with representatives of the big pharmaceutical and cosmetic industry, members of regulatory bodies interested in toxicology, as well as an ethical advisor.


The Advisory Board is invited to attend the annual consortium meetings in order to give their vision and advise regarding the work program, integration and project strategy and to provide an objective assessment of the scientific and innovation/exploitation-related issues.


As SCR&Tox will be implemented in full respect of the legal and ethical European/national/institutional requirements, an external independent Ethics Advisor
has been appointed to oversee the ethical concerns involved in SCR&Tox research.

 

 

Members of the Advisory Board


  • Klaus-Dieter Bremm, Bayer
 

 

 

 

  • Laura Suter-Dick, Roche


Dr. Laura Suter-Dick holds a Ph D in biology and has long term experience in Pharmaceutical Industry. After working as a Ph D-student at Schering AG (Berlin), Laura joined the toxicology department at Sandoz (now Novartis) as a post-doc and then moved to F. Hoffmann-La Roche, Ltd. in 1996. She specialized during her PhD in reproductive biology and then gained experience in the field of toxicology, with a strong focus on molecular toxicology and toxicogenomics. During the last 10 years or so, Laura specialized in mechanistic toxicology; she and her colleagues developed and implemented toxicogenomics and other new technologies, with the main focus on elucidating and predicting toxicity. Currently, she acts as a Senior Scientific Advisor in the Early & Investigative Safety department at F. Hoffmann-La Roche, Ltd., dealing with in vitro assays, mechanistic investigations, and immunosaftey. Her main scientific interest lies on new technologies and their application for the mechanistic understanding of cell biology and toxicology.